Surgery Dosing Calculator

To calculate dosage, use this unique Dosing Calculator, which makes determination of individualized loading doses of Humate-P fast, easy, and convenient.

Humate-P von Willebrand Disease Dosing Calculator

kg 5 10 15 20 25 30 35 40 45 50 55 60 65 70
lb 11 22 33 44 55 66 77 88 99 110 121 132 143 154
Δ IU/dL*                            
10 25 50 75 100 125 150 175 200 225 250 275 300 325 350
20 50 100 150 200 250 300 350 400 450 500 550 600 650 700
30 75 150 225 300 375 450 525 600 675 750 825 900 975 1050
40 100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400
50 125 250 375 500 625 750 875 1000 1125 1250 1375 1500 1625 1750
60 150 300 450 600 750 900 1050 1200 1350 1500 1650 1800 1950 2100
70 175 350 525 700 875 1050 1225 1400 1575 1750 1925 2100 2275 2450
80 200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800
90 225 450 675 900 1125 1350 1575 1800 2025 2250 2475 2700 2925 3150
100 250 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500
kg 75 80 85 90 95 100 105 110 115 120 125 130 135 140
lb 165 176 187 198 209 220 231 242 253 264 275 286 297 308
Δ IU/dL*                            
10 375 400 425 450 475 500 525 550 575 600 625 650 675 700
20 750 800 850 900 950 1000 1050 1100 1150 1200 1250 1300 1350 1400
30 1125 1200 1275 1350 1425 1500 1575 1650 1725 1800 1875 1950 2025 2100
40 1500 1600 1700 1800 1900 2000 2100 2200 2300 2400 2500 2600 2700 2800
50 1875 2000 2125 2250 2375 2500 2625 2750 2875 3000 3125 3250 3375 3500
60 2250 2400 2550 2700 2850 3000 3150 3300 3450 3600 3750 3900 4050 4200
70 2625 2800 2975 3150 3325 3500 3675 3850 4025 4200 4375 4550 4725 4900
80 3000 3200 3400 3600 3800 4000 4200 4400 4600 4800 5000 5200 5400 5600
90 3375 3600 3825 4050 4275 4500 4725 4950 5175 5400 5625 5850 6075 6300
100 3750 4000 4250 4500 4750 5000 5250 5500 5750 6000 6250 6500 6750 7000

*Δ IU/dL is defined as Target Level (VWF:RC0) - Baseline Level (VWF:RCo)

These calculations are to be used only with Humate-P and are applicable for VWF:RCo loading dose calculations for the prevention of excessive bleeding during and after surgery for all types of VWD.

General Rule: Doses are calculated based on an expected in vivo recovery of 2.0 IU/dL rise in VWF:RCo activity per every IU/kg of VWF:RCo administered.

Please see full dosing recommendations for Humate-P in the full prescribing information.


Printer friendly version        Download as PDF        Dosage calculation page

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Humate-P® is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations. Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with risk factors for thrombosis.

Humate-P is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions (reported by >5% of subjects) were allergic/anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, and edema. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided here is primarily intended for use by physicians and other healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.

Treatment for VWD patients

© CSL Behring 2018. The product information presented on this site is intended for US residents only. 11-HUM-082